Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease-Reference-Cited by-同舟云学术

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease

Published:2020-03 Issue:3 Volume:18 Page:637-646.e11
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Dreesen Erwin^ORCID,Baert Filip,Laharie David,Bossuyt Peter^ORCID,Bouhnik Yoram,Buisson Anthony^ORCID,Lambrecht Guy,Louis Edouard,Oldenburg Bas,Pariente Benjamin,Pierik Marieke,van der Woude C. Janneke,D’Haens Geert,Vermeire Séverine,Gils Ann^ORCID

Funder

Research Foundation Flanders

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference23 articles.

1. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target;Peyrin-Biroulet;Am J Gastroenterol,2015

2. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease;Rutgeerts;Gastroenterology,2004

3. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease;Rutgeerts;Gastrointest Endosc,2006

4. Infliximab, azathioprine, or combination therapy for Crohn’s disease;Colombel;N Engl J Med,2010

5. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease;Maser;Clin Gastroenterol Hepatol,2006

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease;Frontiers in Pharmacology;2024-08-27

2. Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study;Gastroenterología y Hepatología (English Edition);2024-08

3. Therapeutic Drug Monitoring and Biomarkers; towards Better Dosing of Antimicrobial Therapy;Pharmaceutics;2024-05-17

4. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17

5. The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model;Pediatric Drugs;2024-03-20